Mutation of NRAS is a Rare Genetic Event in Ovarian Low-Grade Serous Carcinoma

Deyin Xing; Yohan Suryo Rahmanto; Felix Zeppernick; Charlotte G Hannibal; Susanne K Kjaer; Russell Vang; Ie-Ming Shih; Tian-Li Wang

doi:10.1016/j.humpath.2017.08.021

Mutation of NRAS is a Rare Genetic Event in Ovarian Low-Grade Serous Carcinoma

Deyin Xing, Yohan Suryo Rahmanto, Felix Zeppernick, Charlotte G Hannibal, Susanne K Kjaer, Russell Vang, Ie-Ming Shih, Tian-Li Wang

Department of Clinical Medicine

8 Citations (Scopus)

Abstract

Activating mutations involving the members of the RAS signaling pathway, including KRAS, NRAS, and BRAF, have been reported in ovarian low-grade serous carcinoma and its precursor lesion, serous borderline tumor (SBT). Whether additional genetic alterations in the RAS oncogene family accumulate during the progression of SBT to invasive low-grade serous carcinoma (LGSC) remains largely unknown. Although mutations of KRAS and BRAF occur at a very early stage of progression, even preceding the development of SBT, additional driving events, such as NRAS mutations, have been postulated to facilitate progression. In this study, we analyzed NRAS exon 3 mutational status in 98 cases that were diagnosed with SBT/atypical proliferative serous tumor, noninvasive LGSC, or invasive LGSC. Of the latter, NRAS Q61R (CAA to CGA) mutations were detected in only 2 of 56 (3.6%) cases. The same mutation was not detected in any of the SBTs (atypical proliferative serous tumors) or noninvasive LGSCs. Mutational analysis for hotspots in KRAS and BRAF demonstrated a wild-type pattern of KRAS and BRAF in one of the NRAS-mutated cases. Interestingly, another LGSC case with NRAS mutation harbored a concurrent BRAF V600L mutation. These findings indicate that, although recurrent NRAS mutations are present, their low prevalence indicates that NRAS plays a limited role in the development of LGSC. Further studies to identify other oncogenic events that drive LGSC progression are warranted.

Original language	English
Journal	Human Pathology
Volume	68
Pages (from-to)	87-91
Number of pages	5
ISSN	0046-8177
DOIs	https://doi.org/10.1016/j.humpath.2017.08.021
Publication status	Published - Oct 2017

Keywords

Journal Article

Access to Document

10.1016/j.humpath.2017.08.021

Cite this

@article{180aca8d943c40ce9252aa84df2da3b8,

title = "Mutation of NRAS is a Rare Genetic Event in Ovarian Low-Grade Serous Carcinoma",

abstract = "Activating mutations involving the members of the RAS signaling pathway, including KRAS, NRAS, and BRAF, have been reported in ovarian low-grade serous carcinoma and its precursor lesion, serous borderline tumor (SBT). Whether additional genetic alterations in the RAS oncogene family accumulate during the progression of SBT to invasive low-grade serous carcinoma (LGSC) remains largely unknown. Although mutations of KRAS and BRAF occur at a very early stage of progression, even preceding the development of SBT, additional driving events, such as NRAS mutations, have been postulated to facilitate progression. In this study, we analyzed NRAS exon 3 mutational status in 98 cases that were diagnosed with SBT/atypical proliferative serous tumor, noninvasive LGSC, or invasive LGSC. Of the latter, NRAS Q61R (CAA to CGA) mutations were detected in only 2 of 56 (3.6%) cases. The same mutation was not detected in any of the SBTs (atypical proliferative serous tumors) or noninvasive LGSCs. Mutational analysis for hotspots in KRAS and BRAF demonstrated a wild-type pattern of KRAS and BRAF in one of the NRAS-mutated cases. Interestingly, another LGSC case with NRAS mutation harbored a concurrent BRAF V600L mutation. These findings indicate that, although recurrent NRAS mutations are present, their low prevalence indicates that NRAS plays a limited role in the development of LGSC. Further studies to identify other oncogenic events that drive LGSC progression are warranted.",

keywords = "Journal Article",

author = "Deyin Xing and Rahmanto, {Yohan Suryo} and Felix Zeppernick and Hannibal, {Charlotte G} and Kjaer, {Susanne K} and Russell Vang and Ie-Ming Shih and Tian-Li Wang",

note = "Copyright {\textcopyright} 2017. Published by Elsevier Inc.",

year = "2017",

month = oct,

doi = "10.1016/j.humpath.2017.08.021",

language = "English",

volume = "68",

pages = "87--91",

journal = "Human Pathology",

issn = "0046-8177",

publisher = "W.B.Saunders Co.",

}

TY - JOUR

T1 - Mutation of NRAS is a Rare Genetic Event in Ovarian Low-Grade Serous Carcinoma

AU - Xing, Deyin

AU - Rahmanto, Yohan Suryo

AU - Zeppernick, Felix

AU - Hannibal, Charlotte G

AU - Kjaer, Susanne K

AU - Vang, Russell

AU - Shih, Ie-Ming

AU - Wang, Tian-Li

PY - 2017/10

Y1 - 2017/10

N2 - Activating mutations involving the members of the RAS signaling pathway, including KRAS, NRAS, and BRAF, have been reported in ovarian low-grade serous carcinoma and its precursor lesion, serous borderline tumor (SBT). Whether additional genetic alterations in the RAS oncogene family accumulate during the progression of SBT to invasive low-grade serous carcinoma (LGSC) remains largely unknown. Although mutations of KRAS and BRAF occur at a very early stage of progression, even preceding the development of SBT, additional driving events, such as NRAS mutations, have been postulated to facilitate progression. In this study, we analyzed NRAS exon 3 mutational status in 98 cases that were diagnosed with SBT/atypical proliferative serous tumor, noninvasive LGSC, or invasive LGSC. Of the latter, NRAS Q61R (CAA to CGA) mutations were detected in only 2 of 56 (3.6%) cases. The same mutation was not detected in any of the SBTs (atypical proliferative serous tumors) or noninvasive LGSCs. Mutational analysis for hotspots in KRAS and BRAF demonstrated a wild-type pattern of KRAS and BRAF in one of the NRAS-mutated cases. Interestingly, another LGSC case with NRAS mutation harbored a concurrent BRAF V600L mutation. These findings indicate that, although recurrent NRAS mutations are present, their low prevalence indicates that NRAS plays a limited role in the development of LGSC. Further studies to identify other oncogenic events that drive LGSC progression are warranted.

AB - Activating mutations involving the members of the RAS signaling pathway, including KRAS, NRAS, and BRAF, have been reported in ovarian low-grade serous carcinoma and its precursor lesion, serous borderline tumor (SBT). Whether additional genetic alterations in the RAS oncogene family accumulate during the progression of SBT to invasive low-grade serous carcinoma (LGSC) remains largely unknown. Although mutations of KRAS and BRAF occur at a very early stage of progression, even preceding the development of SBT, additional driving events, such as NRAS mutations, have been postulated to facilitate progression. In this study, we analyzed NRAS exon 3 mutational status in 98 cases that were diagnosed with SBT/atypical proliferative serous tumor, noninvasive LGSC, or invasive LGSC. Of the latter, NRAS Q61R (CAA to CGA) mutations were detected in only 2 of 56 (3.6%) cases. The same mutation was not detected in any of the SBTs (atypical proliferative serous tumors) or noninvasive LGSCs. Mutational analysis for hotspots in KRAS and BRAF demonstrated a wild-type pattern of KRAS and BRAF in one of the NRAS-mutated cases. Interestingly, another LGSC case with NRAS mutation harbored a concurrent BRAF V600L mutation. These findings indicate that, although recurrent NRAS mutations are present, their low prevalence indicates that NRAS plays a limited role in the development of LGSC. Further studies to identify other oncogenic events that drive LGSC progression are warranted.

KW - Journal Article

U2 - 10.1016/j.humpath.2017.08.021

DO - 10.1016/j.humpath.2017.08.021

M3 - Journal article

C2 - 28873354

SN - 0046-8177

VL - 68

SP - 87

EP - 91

JO - Human Pathology

JF - Human Pathology

ER -

Mutation of NRAS is a Rare Genetic Event in Ovarian Low-Grade Serous Carcinoma

Abstract

Keywords

Access to Document

Fingerprint

Cite this